227017-99-4

Usage

Uses

Used in Pharmaceutical Synthesis:
Carbamic acid, (4-aminocyclohexyl)-, phenylmethyl ester (9CI) is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a valuable building block for the development of new drugs, particularly in the areas of medicinal chemistry and drug discovery.
Used in Chemical Reactions as a Reagent:
Carbamic acid, (4-aminocyclohexyl)-, phenylmethyl ester (9CI) serves as a reagent in a range of chemical reactions, facilitating the formation of desired products in organic synthesis. Its presence can enhance reaction efficiency and selectivity, making it a useful tool in the laboratory for chemists.
Used in Organic Chemistry Research:
Carbamic acid, (4-aminocyclohexyl)-, phenylmethyl ester (9CI) is also employed in the field of organic chemistry research. It can be used to explore new reaction pathways, investigate the properties of carbamate esters, and contribute to the understanding of complex organic systems.
Used in Drug Development:
Due to its potential as a pharmaceutical intermediate, Carbamic acid, (4-aminocyclohexyl)-, phenylmethyl ester (9CI) plays a role in drug development. It may be involved in the creation of new therapeutic agents, contributing to the advancement of medicine and healthcare.

Upstream product

• 2615-25-0 trans-1,4-cyclohexyldiamine 
• 501-53-1 benzyl chloroformate 
• 296270-92-3 tert-butyl trans-4-(Cbz-amino)cyclohexylcarbamate 
• 149423-69-8 benzyl (1s,4s)-4-azidocyclohexylcarbamate 
• 509143-03-7 cis-(4-tert-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 3114-70-3 trans-1,4-diaminocyclohexane 

Downstream Products

• 1092493-87-2 2-(trans-4-aminocyclohexyl)isothiazolidine 1,1-dioxide 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION

This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

BISTRIFILATE-BASED FLUOROGENIC PROBES FOR DETECTION OF SUPEROXIDE ANION RADICAL

The invention provides fluorogenic compounds and probes that can be used as reagents for measuring, detecting and/or screening superoxide. The fluorogenic compounds of the invention can produce fluorescence colors, such as green, yellow, red, or far-red. The invention further provides fluorogenic compounds for selectively staining superoxide in the mitochondria of living cells. The invention also provides methods that can be used to measure, directly or indirectly, the presence and/or amount of superoxide in chemical samples and biological samples such as cells and tissues in living organisms, and a high-throughput screening methods for detecting or screening superoxide or compounds that can increase or decrease the level of superoxide in chemical and biological samples.

Binuclear NiII-DpaTyr complex as a high affinity probe for an oligo-aspartate tag tethered to proteins

A complementary recognition pair of a short-peptide tag and a small molecular probe is a versatile molecular tool for protein detection, handling, and purification, and so forth. In this manuscript, we report that the binuclear NiII-DpaTyr (DpaTyr = bis((dipicolylamino)methyl)-tyrosine) complex serves as a strong binding probe for an oligo-aspartate tag tethered to a protein. Among various binuclear metal complexes of M-DpaTyr (M = Zn II, NiII, MnII, CuII, Cd II, CoIII, and FeIII), we have found that NiII-DpaTyr (1-2NiII) displays a strongbinding affinity (apparent binding constant: Kapp≈105M-1) for an oligo-aspartate peptide under neutral aqueous conditions (50 mM HEPES, 100 mM NaCl, pH 7.2). Detailed isothermal-titration calorimetry (ITC) studies reveal that the tri-aspartate D3-tag (DDD) is an optimal sequence recognized by 1-2NiII in a 1:1 binding stoichiometry. On the other hand, other metal complexes of DpaTyr, except for NiII-and ZnII- DpaTyr, show a negligible binding affinity for the oligo-aspartate peptide. The binding affinity was greatly enhanced in the pair between the dimer of Ni II-DpaTyr and the repeated D3 tag peptide (D3x2), such as DDDXXDDD, on the basis of the multivalent coordination interaction between them. Most notably, a remarkably high-binding affinity (Kapp 10 9M-1) was achieved between the NiII-DpaTyr dimer 4-4NiII and the D3 x 2 tag peptide (DDDNGDDD). This affinity is ≈fold stronger than that observed in the binding pair of the Zn II-DpaTyr (4-4ZnII) and the D4x2 tag (DDDDGDDDD), a useful tagprobe pair previously reported by us. The recognition pair of the Ni II-DpaTyr probe and the D3 x 2 tag can also work effectively on a protein surface, that is, 4-4NiII is strongly bound to the FKBP12 protein tethered with the D3 x 2 tag (DDDNGDDD) with a large Kapp value of 5 x 108 m-1. Taking advantage of the strong-binding affinity, this pair was successfully applied to the selective inactivation of the tagfused (β-galactosidase by using the chromophore-assisted light inactivation (CALI) technique under crude conditions, such as cell lysate.

INHIBITORS OF PROTEIN KINASES

The present invention is directed to compounds of formula (I)-(II) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

QUINOLINE, TETRAHYDROQUINOLINE AND PYRIMIDINE DERIVATIVES AS MCH ANTAGONIST

The present invention relates to compounds of the Formula (I) wherein Q is: which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

2-6-diaminopurine precursors

The present invention relates to compounds of formula (IV): STR1 wherein Ra and Rb each represent a hydrogen atom or together form an alkylidene group.

Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands

Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states. Also disclosed are anaphylatoxin receptor ligand compositions